George Papandreou - 08 May 2024 Form 4 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
General Manager and Senior Vice President, Focal Therapies
Signature
/s/ Matthew R. Schob, Attorney-in-Fact
Issuer symbol
OBIO
Transactions as of
08 May 2024
Net transactions value
$0
Form type
4
Filing time
10 May 2024, 17:23:29 UTC
Previous filing
29 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OBIO Common Stock, par value $0.0001 per share ("Common Stock") Award $0 +22,000 +110% $0.000000 42,000 08 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OBIO Stock Option (Right to Buy) Award $0 +33,000 $0.000000 33,000 08 May 2024 Common Stock $33,000 $4.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as follows: (i) 3,300 RSUs will vest on May 22, 2025, and (ii) the remaining 18,700 RSUs will vest in equal installments on August 22, 2025, November 22, 2025, December 24, 2025, May 22, 2026, August 22, 2026, November 22, 2026, March 25, 2027, May 22, 2027, August 22, 2027, November 22, 2027, March 25, 2028 and May 22, 2028, subject to the Reporting Person's continuous service through such dates.
F2 The stock options will vest as follows: (i) 8,250 of the stock options will vest on May 8, 2025 (the "Vesting Date") and (ii) the remaining 24,750 of the stock options will vest in equal installments every three months on the same day of the month as the Vesting Date, starting on August 8, 2025, subject to the Reporting Person's continuous service through such dates.

Remarks:

General Manager and Senior Vice President, Focal Therapies